News

CAMBRIDGE, MA –March 25, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming virtual investor events in April 2021. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel CNS Day on April 1, 2021 at 2:30pm ET and the Company is participating in the Needham […] » Full Story

CAMBRIDGE, Mass. – January 25, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the Winter Private Company Showcase, co-hosted by Solebury Trout, Oppenheimer and White & Case on Friday, January 29, 2021 at 11am Eastern Time. The presentation will provide an overview of the Company’s […] » Full Story

CAMBRIDGE, MA –November 18, 2020 – Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This latest grant builds on Caraway’s drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the […] » Full Story

CAMBRIDGE, MA –November 10, 2020 – Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET. Caraway’s President and Chief Scientific Officer, Magdalene Moran, […] » Full Story

Caraway Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced it has appointed Martin D. Williams as Chief Executive Officer. » Full Story

Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics. » Full Story

Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing round totaling $23 million. » Full Story